Q2 EPS Forecast for vTv Therapeutics Increased by Analyst

vTv Therapeutics Inc. (NASDAQ:VTVT) – Analysts at HC Wainwright increased their Q2 2026 EPS estimates for shares of vTv Therapeutics in a research report issued on Thursday, May 14th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will post earnings per share of ($0.51) for the quarter, up from their previous forecast of ($0.64). The consensus estimate for vTv Therapeutics’ current full-year earnings is ($2.28) per share. HC Wainwright also issued estimates for vTv Therapeutics’ Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at $0.02 EPS, FY2027 earnings at ($3.17) EPS, FY2028 earnings at ($3.45) EPS, FY2029 earnings at ($3.52) EPS and FY2030 earnings at ($3.36) EPS.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 EPS for the quarter, topping the consensus estimate of $0.21 by $1.44. The company had revenue of $36.84 million during the quarter, compared to analysts’ expectations of $20.00 million.

VTVT has been the subject of several other reports. BTIG Research restated a “buy” rating and set a $49.00 price objective on shares of vTv Therapeutics in a research note on Wednesday, March 11th. Zacks Research raised shares of vTv Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Wall Street Zen raised shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of vTv Therapeutics in a report on Friday, March 27th. Finally, Evercore initiated coverage on shares of vTv Therapeutics in a report on Thursday, March 12th. They set an “outperform” rating and a $44.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $53.00.

vTv Therapeutics Stock Performance

NASDAQ VTVT opened at $35.49 on Tuesday. vTv Therapeutics has a one year low of $14.00 and a one year high of $44.00. The company has a market capitalization of $139.83 million, a price-to-earnings ratio of -38.16 and a beta of 0.26. The company’s 50-day simple moving average is $35.92 and its two-hundred day simple moving average is $34.27.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. acquired a new position in shares of vTv Therapeutics during the 4th quarter valued at about $221,000. Geode Capital Management LLC boosted its position in shares of vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after acquiring an additional 12,896 shares during the last quarter. 683 Capital Management LLC acquired a new position in shares of vTv Therapeutics during the 4th quarter valued at about $731,000. Finally, Baker BROS. Advisors LP boosted its position in shares of vTv Therapeutics by 52.4% during the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after acquiring an additional 51,000 shares during the last quarter. Institutional investors and hedge funds own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.